New appointments strengthen Altoida’s position as the inevitable standard for early detection and monitoring in a $7B+ and growing annual brain health diagnostics market
Washington, D.C. — BUSINESSWIRE — Altoida, Inc., a pioneer in AI- and AR-based digital diagnostics for neurological diseases, today announced the appointment of three new distinguished members to its already highly regarded Clinical and Scientific Advisory Board: Mona Flores, MD, former Global Head of Medical AI at NVIDIA; Bryan J. Hansen, PhD, former Director of Innovative Health, Portfolio Launch Strategy at Johnson & Johnson Innovative Medicine; and Michael Zuendel, founder of Legacy Bridge Private Family Offices, founder of “Initiative to change the ‘D-Word’”, and a nationally recognized Alzheimer's patient advocate. Their combined expertise across AI, pharma, and patient advocacy underscores Altoida’s leadership as the first category-defining digital brain health assessment platform, advancing through pivotal study and FDA submission, and preparing the market for rapid clinical adoption once cleared.
These appointments mark a pivotal moment for Altoida as it advances toward adoption of its Digital NeuroMarker Platform, a 10-minute, smart device-based, self-administered AR- and AI-powered tool that is designed to enable multimodal detection of subtle and early cognitive changes associated with neurodegenerative diseases like Alzheimer’s.
“The addition of Dr. Flores, Dr. Hansen, and Mr. Zuendel reflects Altoida’s unique position at the intersection of AI innovation, clinical validation, and patient advocacy,” said Marc Jones, CEO of Altoida. “Their expertise will be invaluable as we advance our pivotal study and expand pharma partnerships and, once FDA-cleared, support rapid clinical adoption of our Digital NeuroMarker Platform. Together, we are building the inevitable standard in digital brain health diagnostics and bringing precision neurology into frontline healthcare at scale.”
Dr. Mona Flores brings unmatched expertise in applying advanced AI to transform healthcare. At NVIDIA, she led global initiatives that harnessed cutting-edge computational power to revolutionize medical imaging, digital health, and drug discovery. She will help guide Altoida in advancing its AI-powered NeuroMarker Platform toward readiness and realization of broad clinical and commercial use.
“Altoida is the leader in applying AI to cognitive diagnostics, and I am honored to join at such a critical juncture,” said Dr. Flores. “Harnessing AI responsibly can redefine how we detect, diagnose, and treat neurological diseases like Alzheimer’s, and Altoida is setting the standard for how this should be done. I look forward to helping advance this vision for clinicians and patients worldwide.”
Dr. Bryan Hansen brings over a decade of experience in academia and pharma at the intersection of neuroscience, digital health, and clinical research. Most recently at Johnson & Johnson Innovative Medicine, he led the Portfolio Launch Strategy for Innovative Health, having previously directed the Data Science & Digital Health strategy across the neurodegeneration portfolio, where he advanced the use of digital health technologies to accelerate development and patient-centric trials.
“Altoida is uniquely positioned to bring AI-driven digital biomarkers into real-world use,” said Dr. Hansen. “By bridging rigorous science with practical deployment, Altoida’s Digital NeuroMarker Platform has the potential to revolutionize the development of new therapies and improve clinicians’ ability to detect and monitor disease at earlier stages.”
Complementing this scientific expertise, Altoida is honored to welcome Michael Zuendel to its Scientific Advisory Board. As an individual living with Alzheimer’s and the founder of the Initiative to change the “D-Word”, Zuendel brings the powerful voice of both advocate and patient. His perspective will help ensure Altoida’s innovations remain closely aligned with the real needs of patients, families, and the broader Alzheimer’s and cognitive health community.
“My mission has always been to help people understand that a diagnosis does not define them,” said Zuendel. “By joining Altoida, I hope to amplify the patient voice and ensure that the technologies shaping the future of brain health are built with empathy, dignity and hope, and with the recognition that earlier assessment, like Altoida’s, offers the hope for better planning, better care and better outcomes.”
To learn more about Altoida and its mission to redefine precision neurology, visit www.altoida.com.
About Altoida
Altoida is defining a new category in neurological care with a first-of-its-kind, AI- and AR-powered digital biomarker platform for clinical-grade cognitive and functional assessment. The company’s 10-minute, self-administered Digital NeuroMarker Platform captures millions of raw multimodal data points across motor, speech, and cognitive domains, designed to enable earlier and more objective detection of Mild Cognitive Impairment (MCI) and Alzheimer’s disease.
Built on 20+ years of scientific research and over 42,000 tests across more than 20,000 participants in academic, research, and global pharma trials, Altoida’s Digital NeuroMarker Platform has been independently researched and peer-reviewed in Nature Digital Medicine.
With an estimated 200M undiagnosed MCI patients worldwide, many of whom are eligible for new Alzheimer’s drugs, payors and providers are demanding scalable solutions. With billing codes available, treatments on the market and more emerging, Altoida is uniquely positioned to meet this $7B+ near-term market and to empower clinicians to deliver earlier interventions when they matter most.
For more information, visit www.altoida.com. Follow us on LinkedIn and X @altoida.
Media Contact:
Jenna Hanson
jenna.hanson@altoida.com
